Related Experiment Videos
[Therapeutic results with the aromatic retinoid (Tigason) in Sharp syndrome and progressive scleroderma]
Abstract:
As experimental findings indicated inhibitory action of aromatic retinoid on microtubule polymerisation and collagen metabolism of mesenchymal cells, we decided to treat 5 patients suffering from progressive systemic sclerosis as well as 3 patients with Sharp's syndrome with aromatic retinoid (Tigason). All 8 patients of this preliminary study responded positively to this therapy, but there were individual differences. The dosage corresponded to that applied in psoriasis. There were no severe side effects observed. In our opinion, these results justify the application of aromatic retinoid in patients suffering from progressive systemic sclerosis or Sharp's syndrome.
Insights
Aromatic retinoid therapy showed positive responses in patients with progressive systemic sclerosis and Sharp's syndrome. This preliminary study suggests potential benefits for these autoimmune conditions.
Area of Science:
- Pharmacology
- Immunology
- Dermatology
Context:
- Progressive systemic sclerosis and Sharp's syndrome are debilitating autoimmune diseases.
- Mesenchymal cell collagen metabolism and microtubule polymerization are implicated in these conditions.
- Aromatic retinoids have demonstrated inhibitory effects on these cellular processes.
Purpose:
- To investigate the efficacy of aromatic retinoid (Tigason) in treating patients with progressive systemic sclerosis and Sharp's syndrome.
- To assess the safety and tolerability of aromatic retinoid therapy in this patient cohort.
Summary:
- Eight patients (5 with progressive systemic sclerosis, 3 with Sharp's syndrome) received aromatic retinoid treatment.
- All patients exhibited positive responses to the therapy, with observed individual variations.
- The dosage used was consistent with that for psoriasis treatment, and no severe adverse effects were reported.
Impact:
- These findings suggest that aromatic retinoids may be a viable therapeutic option for progressive systemic sclerosis and Sharp's syndrome.
- Further research is warranted to confirm these preliminary results and explore optimal treatment protocols.